Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437870 | 0.84 | KMT2A (0.48) | KMT2AMEN1TDP1MAPTHSP90AA1 | |
| SCHEMBL10669426 | 0.81 | MEN1 (0.49) | KMT2AMEN1TDP1MAPTHSP90AA1 | |
| SCHEMBL10669435 | 0.81 | MEN1 (0.49) | KMT2AMEN1TDP1MAPTHSP90AA1 | |
| SCHEMBL10368769 | 0.78 | MEN1 (0.76) | KMT2AMEN1TDP1MAPTHSP90AA1 | |
| SCHEMBL2214289 | 0.77 | KMT2A (0.48) | KMT2AMEN1TDP1MAPTHSP90AA1 | |
| SCHEMBL1967461 | 0.77 | KMT2A (0.48) | KMT2AMEN1TDP1MAPTHSP90AA1 | |
| SCHEMBL12418543 | 0.76 | MEN1 (0.58) | KMT2AMEN1TDP1MAPTHSP90AA1 | |
| SCHEMBL10943652 | 0.75 | KMT2A (0.54) | KMT2AMEN1TDP1MAPTHSP90AA1 | |
| SCHEMBL10364639 | 0.75 | MEN1 (0.57) | KMT2AMEN1TDP1MAPTHSP90AA1 | |
| SCHEMBL12418678 | 0.74 | MEN1 (0.56) | KMT2AMEN1TDP1MAPTHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110177950-A1 | Imidazole and Triazole Compounds, Their Use and Agents Containing the Same | BASF SE (DE) | 2011-07-21 | — | — | US | disclosed |
| US-20110177950-A1 | Imidazole and Triazole Compounds, Their Use and Agents Containing the Same | BASF SE (DE) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177950-A1 | Imidazole and Triazole Compounds, Their Use and Agents Containing the Same | COX4I1, CYP2C19, CYP3A43 | KMT2A 1323/4885MEN1 986/4885TDP1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.